ATE495739T1 - Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa - Google Patents
Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopaInfo
- Publication number
- ATE495739T1 ATE495739T1 AT04782161T AT04782161T ATE495739T1 AT E495739 T1 ATE495739 T1 AT E495739T1 AT 04782161 T AT04782161 T AT 04782161T AT 04782161 T AT04782161 T AT 04782161T AT E495739 T1 ATE495739 T1 AT E495739T1
- Authority
- AT
- Austria
- Prior art keywords
- methods
- carbidopa
- levodopa
- pharmaceutical compositions
- compositions
- Prior art date
Links
- IVTMXOXVAHXCHI-YXLMWLKOSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid;(2s)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 IVTMXOXVAHXCHI-YXLMWLKOSA-N 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 3
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49925603P | 2003-08-29 | 2003-08-29 | |
| US50555103P | 2003-09-24 | 2003-09-24 | |
| US55986404P | 2004-04-06 | 2004-04-06 | |
| US58644204P | 2004-07-08 | 2004-07-08 | |
| PCT/US2004/027607 WO2005023185A2 (en) | 2003-08-29 | 2004-08-26 | Pharmaceutical compositions and method of using levodopa and carbidopa |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE495739T1 true ATE495739T1 (de) | 2011-02-15 |
Family
ID=34280054
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04782161T ATE495739T1 (de) | 2003-08-29 | 2004-08-26 | Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20050070608A1 (de) |
| EP (1) | EP1670450B8 (de) |
| JP (1) | JP5160786B2 (de) |
| AT (1) | ATE495739T1 (de) |
| AU (1) | AU2004270174B2 (de) |
| CA (1) | CA2536175C (de) |
| DE (1) | DE602004031134D1 (de) |
| MX (1) | MXPA06002344A (de) |
| WO (1) | WO2005023185A2 (de) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8815950B2 (en) | 2003-08-29 | 2014-08-26 | Janssen Biotech, Inc. | Pharmaceutical compositions and method of using levodopa and carbidopa |
| SE0401842D0 (sv) | 2004-07-12 | 2004-07-12 | Dizlin Medical Design Ab | Infusion and injection solution of levodopa |
| US20070148238A1 (en) * | 2005-06-23 | 2007-06-28 | Spherics, Inc. | Dosage forms for movement disorder treatment |
| WO2007011701A1 (en) * | 2005-07-15 | 2007-01-25 | Transform Pharmaceuticals, Inc. | Novel hydrochloride salts of levodopa |
| WO2007073325A1 (en) * | 2005-12-20 | 2007-06-28 | Cereuscience Ab | Method and composition for treating and diagnosing restless legs syndrome |
| EP2063867A2 (de) * | 2006-12-22 | 2009-06-03 | Combinatorx, Incorporated | Pharmazeutische zusammensetzungen zur behandlung von morbus parkinson und damit verbundenen leiden |
| CA2682888A1 (en) * | 2007-04-06 | 2008-10-16 | Transform Pharmaceuticals, Inc. | Systems and methods for delivering a fluid drug |
| AU2014202306B2 (en) * | 2007-12-28 | 2016-09-08 | Impax Laboratories, Llc | Controlled release formulations of levodopa and uses thereof |
| KR101451564B1 (ko) | 2007-12-28 | 2014-11-04 | 임팩스 라보라토리즈, 인코포레이티드 | 레보도파 방출 제어형 제제 및 이의 용도 |
| SG10201505101VA (en) * | 2009-05-19 | 2015-07-30 | Neuroderm Ltd | Compositions For Continuous Administration Of Dopa Decarboxylase Inhibitors |
| MX336663B (es) * | 2009-09-18 | 2016-01-27 | Sanofi Sa | Formulaciones en comprimido de la (4'-trifluorometilfenil)amida del acido (z)-2-ciano-3-hidroxibut-2-enoico con estabilidad mejorada. |
| WO2013035053A2 (en) * | 2011-09-09 | 2013-03-14 | Kareus Therapeutics, Sa | Novel conjugation-facilitated transport of drugs across blood brain barrier |
| US10987313B2 (en) | 2013-10-07 | 2021-04-27 | Impax Laboratories, Llc | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
| JP6506271B2 (ja) | 2013-10-07 | 2019-04-24 | インパックス ラボラトリーズ、 インコーポレイテッドＩｍｐａｘ Ｌａｂｏｒａｔｏｒｉｅｓ， Ｉｎｃ． | レボドパ及び／又はレボドパのエステルの粘膜付着性制御放出配合物、並びにその使用 |
| US10258585B2 (en) | 2014-03-13 | 2019-04-16 | Neuroderm, Ltd. | DOPA decarboxylase inhibitor compositions |
| WO2015136538A1 (en) * | 2014-03-13 | 2015-09-17 | Neuroderm Ltd | Dopa decarboxylase inhibitor compositions |
| CA3175785A1 (en) | 2014-09-04 | 2016-03-10 | Intrance International Ab | Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a comt inhibitor and method of administration thereof |
| RU2021103000A (ru) | 2014-10-21 | 2021-03-01 | Эббви Инк. | Пролекарства карбидопа и l-dopa и их применение для лечения болезни паркинсона |
| WO2016179540A1 (en) | 2015-05-06 | 2016-11-10 | Synagile Corporation | Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use |
| WO2017039525A1 (en) | 2015-09-04 | 2017-03-09 | Lobsor Pharmaceuticals Aktiebolag | Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor |
| KR102434254B1 (ko) * | 2016-04-11 | 2022-08-18 | 유니버시티 오브 캔버라 | 레보도파, 항산화제 및 수성 담체를 포함하는 안과 조성물 |
| JP2019515908A (ja) * | 2016-04-20 | 2019-06-13 | アッヴィ・インコーポレイテッド | カルビドパ及びｌ−ドパプロドラッグ並びに使用方法 |
| HRP20210599T1 (hr) | 2017-06-05 | 2021-05-14 | Dizlin Pharmaceuticals Ab | Otopina levodope za infuziju |
| EP3735298A4 (de) * | 2018-01-05 | 2021-10-06 | Impel Neuropharma Inc. | Intranasale verabreichung von levodopa-pulver durch n durch eine olfaktorische präzisionsvorrichtung |
| HRP20251502T1 (hr) | 2018-03-23 | 2026-02-13 | Lobsor Pharmaceuticals Aktiebolag | Kontinuirana primjena farmaceutskog pripravka za liječenje neurodegenerativnih poremećaja |
| WO2020018959A1 (en) | 2018-07-19 | 2020-01-23 | Impel Neuropharma, Inc. | Respiratory tract delivery of levodopa and dopa decarboxylase inhibitor for treatment of parkinson's disease |
| EP3880210A1 (de) | 2018-11-15 | 2021-09-22 | Abbvie Inc. | Pharmazeutische formulierungen zur subkutanen verabreichung |
| US11213502B1 (en) | 2020-11-17 | 2022-01-04 | Neuroderm, Ltd. | Method for treatment of parkinson's disease |
| US11844754B2 (en) | 2020-11-17 | 2023-12-19 | Neuroderm, Ltd. | Methods for treatment of Parkinson's disease |
| US11331293B1 (en) | 2020-11-17 | 2022-05-17 | Neuroderm, Ltd. | Method for treatment of Parkinson's disease |
| US11986449B2 (en) | 2020-12-22 | 2024-05-21 | Amneal Pharmaceuticals Llc | Levodopa dosing regimen |
| WO2022140448A1 (en) | 2020-12-22 | 2022-06-30 | Amneal Pharmaceuticals Llc | Levodopa dosing regimen |
| US12161612B2 (en) | 2023-04-14 | 2024-12-10 | Neuroderm, Ltd. | Methods and compositions for reducing symptoms of Parkinson's disease |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3928431A (en) * | 1972-07-14 | 1975-12-23 | Medica Ab Oy | Method of isolating L-dopa from a aqueous solution thereof |
| US4771073A (en) * | 1985-12-30 | 1988-09-13 | Merck & Co., Inc. | Rectally absorbable form of L-dopa |
| EP0252290B1 (de) * | 1986-06-10 | 1992-06-03 | CHIESI FARMACEUTICI S.p.A. | Levodopa-methyl-ester enthaltende pharmazeutische Zusammensetzungen, ihre Herstellung und therapeutische Verwendungen |
| US4829875A (en) * | 1988-09-12 | 1989-05-16 | Queen's University At Kingston | Over-centre locking tool |
| US5190763A (en) * | 1990-05-07 | 1993-03-02 | Alza Corporation | Dosage form indicated for the management of abnormal posture, tremor and involuntary movement |
| DE4101873C2 (de) * | 1991-01-23 | 1993-12-09 | Isis Pharma Gmbh | Peroral applizierbare Arzneiform zur Behandlung zentraler Dopaminmangelzustände |
| US5354885A (en) * | 1992-12-24 | 1994-10-11 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Process for preparing ethyl ester of L-DOPA |
| US5607969A (en) * | 1992-12-24 | 1997-03-04 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | L-DOPA ethyl ester to treat Parkinson's disease |
| US5881926A (en) | 1993-03-11 | 1999-03-16 | Taro Pharmaceutical Industries, Ltd. | Pharmaceutical compositions in semisolid form and a device for administration thereof |
| US6166081A (en) * | 1997-10-09 | 2000-12-26 | Kushnir; Moshe | Methods and apparatus for treatment of Parkinson's disease |
| US6376545B1 (en) * | 1998-11-10 | 2002-04-23 | Teva Pharmaceutical Industries, Ltd. | Dispersible compositions containing L-DOPA ethyl ester |
| US6531153B2 (en) * | 2001-05-29 | 2003-03-11 | Drugtech Corporation | Composition with sustained release of levodopa and carbidopa |
| WO2003053400A1 (en) * | 2001-12-19 | 2003-07-03 | Alza Corporation | Formulation & dosage form for the controlled delivery of therapeutic agents |
-
2004
- 2004-08-26 CA CA2536175A patent/CA2536175C/en not_active Expired - Fee Related
- 2004-08-26 US US10/926,702 patent/US20050070608A1/en not_active Abandoned
- 2004-08-26 EP EP04782161A patent/EP1670450B8/de not_active Expired - Lifetime
- 2004-08-26 WO PCT/US2004/027607 patent/WO2005023185A2/en not_active Ceased
- 2004-08-26 AU AU2004270174A patent/AU2004270174B2/en not_active Ceased
- 2004-08-26 MX MXPA06002344A patent/MXPA06002344A/es active IP Right Grant
- 2004-08-26 AT AT04782161T patent/ATE495739T1/de active
- 2004-08-26 JP JP2006524820A patent/JP5160786B2/ja not_active Expired - Fee Related
- 2004-08-26 DE DE602004031134T patent/DE602004031134D1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JP2007504143A (ja) | 2007-03-01 |
| EP1670450A2 (de) | 2006-06-21 |
| EP1670450B1 (de) | 2011-01-19 |
| MXPA06002344A (es) | 2006-05-19 |
| WO2005023185A3 (en) | 2005-05-19 |
| US20050070608A1 (en) | 2005-03-31 |
| AU2004270174A1 (en) | 2005-03-17 |
| DE602004031134D1 (de) | 2011-03-03 |
| HK1085140A1 (en) | 2006-08-18 |
| EP1670450A4 (de) | 2008-08-27 |
| EP1670450B8 (de) | 2011-03-23 |
| CA2536175C (en) | 2013-05-28 |
| CA2536175A1 (en) | 2005-03-17 |
| JP5160786B2 (ja) | 2013-03-13 |
| WO2005023185A2 (en) | 2005-03-17 |
| AU2004270174B2 (en) | 2010-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE495739T1 (de) | Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa | |
| ATE414089T1 (de) | Verwendung von rapamycin und dessen derivaten zur behandlung von knochenverlust | |
| CY1111263T1 (el) | Φαρμακευτικη συνθεση η οποια περιλαμβανει sns-595 και χρησεις αυτης | |
| DE602004014117D1 (de) | Thiazole zur verwendung als inhibitoren von protein-kinasen | |
| ATE521357T1 (de) | Verfahren zur behandlung von hepatitis | |
| EA200870019A1 (ru) | Лактамовые соединения и способы их применения | |
| DK1615952T3 (da) | Fremgangsmåder til behandling af betændelsestilstande med specifikke, til humant angiopoietin-2-bindende midler | |
| EA200601776A1 (ru) | Метадоновые композиции местного действия и способы их применения | |
| BRPI0507680A (pt) | partìculas de fosfato de cálcio terapêuticas e métodos de fabricação e uso das mesmas | |
| DK1654253T3 (da) | Substituerede 3-pyrrolidinindolderivater | |
| CY1113116T1 (el) | Υποκατεστημενες 4-αμινοκυκλοεξανολες | |
| DE602005026866D1 (de) | Vewendung von dreidimensionalem kultiviertem gewebe zur behandlung von kongestivem herzversagen | |
| DE602004017326D1 (de) | Tetrahydrocarbazolderivate und deren pharmazeutische verwendung | |
| EA200601288A1 (ru) | Производные 1,3-дифенилпроп-2-ен-1-она, способ их получения и применение | |
| DE602004019541D1 (de) | Cycloalkyläbü kondensierte indole | |
| CY1110156T1 (el) | Υποκατεστημενες ενωσεις 4,5,6,7-τετραϋδρο-βενζοθειαζολ-2-υλαμινης | |
| DE502004012196D1 (de) | Verwendung von isorhamnetin zur behandlung von depressiven verstimmungen und erkrankungen | |
| DE60137506D1 (de) | Verwendung von polysulfatierten cyclodextrinen zur behandlung von arthrose | |
| DE60326348D1 (de) | Makrozyclen zur behandlung von krebserkrankungen | |
| DE50302552D1 (de) | Verwendung von treosulfan und derivaten davon zur behandlung der multiplen sklerose | |
| ATE272400T1 (de) | Verwendung von tryptophan-derivaten zur spezifischen zytostatischen behandlung von serotonin-produzierenden tumoren | |
| DE602005018941D1 (de) | Verwendung von winterbohnenkraut (satureja montana) oder seinen extrakten zur herstellung von medikamenten zur behandlung von vorzeitiger ejakulation | |
| ATE395055T1 (de) | Pharmazeutische zusammensetzung zur behandlung von hyperhomocysteinämie | |
| ATE454144T1 (de) | Behandlung von malignen neoplasien | |
| ATE425755T1 (de) | 4-aminophenyl-morpholinon-derivate zur behandlung von hepatitis c |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1670450 Country of ref document: EP |